Jefferies Group LLC Akebia Therapeutics, Inc. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $24,497 - $51,292	76,556 Added 60.61%	202,856 $3,000
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $90,936 - $370,059	126,300 New	126,300 $0
Q3 2019 Nov 13, 2019	SELL	$3.55 - $5.4 $135,038 - $205,410	-38,039 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $71,225 - $139,844	17,372 Added 84.06%	38,039 $184,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $119,041 - $192,094	-22,004 Reduced 51.57%	20,667 $169,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $112,413 - $190,832	20,856 Added 95.6%	42,671 $236,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $86,936 - $124,445	-11,685 Reduced 34.88%	21,815 $193,000
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $306,525 - $379,890	33,500 New	33,500 $334,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.